PD -1/PD-L1 monoclonal antibody

DRUG4 trials

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University, Second Affiliated Hospital of Soochow University, Shanghai Zhongshan Hospital, The First Affiliated Hospital with Nanjing Medical University

Conditions

Advanced Lung CancerImmune Checkpoint InhibitorLymphopeniaNSCLC (Advanced Non-small Cell Lung Cancer)Post SurgicalPrimary Central Nervous System Lymphoma (PCNSL)RadiotherapySecondary Central Nervous System Lymphoma (SCNSL)

Early Phase 1

WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody

RecruitingNCT06106152

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityAdvanced Lung Cancer

Start: 2023-12-05End: 2025-12-31Target: 20Updated: 2024-03-26

Phase 2

PRaG-1 Plus PRaG Therapy in Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0)

Not yet recruitingNCT07267234

Second Affiliated Hospital of Soochow UniversityImmune Checkpoint Inhibitor, Lymphopenia, Radiotherapy +1

Start: 2025-12-01End: 2027-09-01Target: 65Updated: 2025-12-05

Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC

Not yet recruitingNCT07353476

Shanghai Zhongshan HospitalNSCLC (Advanced Non-small Cell Lung Cancer), Post Surgical

Start: 2026-06-01End: 2032-06-01Target: 38Updated: 2026-01-20

PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.

RecruitingNCT07410520

The First Affiliated Hospital with Nanjing Medical UniversityPrimary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)

Start: 2026-02-07End: 2029-12-31Target: 50Updated: 2026-02-13